Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50

stock market index In finance, a stock index, or stock market index, is an index that measures a stock market, or a subset of the stock market, that helps investors compare current stock price levels with past prices to calculate market performance. Two of the ...

. Sanofi engages in the

research and development Research and development (R&D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existi ...

, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops

over-the-counter medication Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescr ...

. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).

History

Sanofi-Synthélabo

Sanofi was founded in 1973 as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by

Total Total may refer to: Mathematics * Total, the summation of a set of numbers * Total order, a partial order without incomparable pairs * Total relation, which may also mean ** connected relation (a binary relation in which any two elements are comp ...

), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947, by Sociéte Belge de l'Azote et des Produits Chimiques du Marly; Labaz developed

benziodarone Benziodarone is a vasodilator. * Bufeniode has the same aromatic substitution pattern. See also * Amiodarone * Benzbromarone, the brominated analogue of benziodarone, used as an uricosuric * Dronedarone Dronedarone, sold under the brand nam ...

in 1957. In 1993, Sanofi made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company that had about US$104 million in sales in 1992.Staff, The Pharma Letter. Sept 20, 199
Sanofi Extends Holding in Chinoin
/ref> In that same year, Sanofi's made its first significant venture into the U.S., and strengthened its presence in Eastern Europe, by first partnering with

Sterling Winthrop Sterling Drug was an American global pharmaceutical company, also known as Sterling Winthrop, Inc. in its last years (after the merger with Winthrop-Stearns Inc. which itself resulted from the merger of ''Winthrop Chemical Company Inc.'' and '' ...

and then acquiring the prescription pharmaceuticals business in 1994. Sanofi was incorporated under the laws of France in 1994, as a ''société anonyme'', a form of limited liability company.Sanofi-Synthélab
Form 20F for the Fiscal Year ended 31 December 2002
/ref> Synthélabo was founded in 1970, through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L'Oréal acquired the majority of its share capital. In 1991, Synthelabo acquired Laboratories Delalande and Laboratoires Delagrange, and through this deal picked up the product metoclopramide. Sanofi Synthelabo Logo

Sanofi-Synthélabo was formed in 1999, when Sanofi merged with Synthélabo; at the time of the merger Sanofi was the second largest pharmaceutical group in France in terms of sales and Synthélabo was the third largest. The merged company was based in Paris, France. The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger, including beauty, diagnostics, animal health and nutrition, custom chemicals, and two medical equipment businesses.

Aventis

Aventis was formed in 1999, when French company Rhône-Poulenc S.A. merged with the German corporation

Hoechst Marion Roussel Hoechst AG () was a German chemicals then life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the ...

, which itself was formed from the 1995 merger of Hoechst AG with

Cassella Cassella AG, formerly Leopold Cassella & Co. and Cassella Farbwerke Mainkur AG, commonly known as Cassella, was a German chemical and pharmaceutical company with headquarters in Frankfurt am Main. Founded in 1798 in the Frankfurt Jewish Alley by ...

, Roussel Uclaf and Marion Merrell Dow. Hoechst AG, the majority partner at the time in

, was itself a merger of two of the three forcibly separated subsidiaries of

IG Farben Interessengemeinschaft Farbenindustrie AG (), commonly known as IG Farben (German for 'IG Dyestuffs'), was a German chemical and pharmaceutical conglomerate (company), conglomerate. Formed in 1925 from a merger of six chemical companies—BASF, ...

, exploiter of

Auschwitz Auschwitz concentration camp ( (); also or ) was a complex of over 40 concentration and extermination camps operated by Nazi Germany in occupied Poland (in a portion annexed into Germany in 1939) during World War II and the Holocaust. It con ...

slave labor and supplier of Zyklon B during The Holocaust. The merged company was based in Schiltigheim, near

Strasbourg Strasbourg (, , ; german: Straßburg ; gsw, label=Bas Rhin Alsatian, Strossburi , gsw, label=Haut Rhin Alsatian, Strossburig ) is the prefecture and largest city of the Grand Est region of eastern France and the official seat of the Eu ...

, France.Aventi
Form 20-F for the fiscal year ended 31 December 2002
/ref>Arturo Bris and Christos Cabolis
Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis
Chapter 4 i

Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 26 July 2007Lawton Robert Burns
The Business of Healthcare Innovation
Cambridge University Press, 26 July 2012 At the time of the merger, Rhône-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines), the plant and animal health businesses Rhône-Poulenc Agro, Rhône-Poulenc Animal Nutrition, and

Merial Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets. Overview In August 1997, ...

, and a 67 percent share in Rhodia, a speciality chemicals company. Hoechst, one of the companies resulting from the post-WWII split of

, had seven primary businesses: Hoechst Marion Roussel (pharmaceuticals),

AgrEvo Plant Genetic Systems (PGS), since 2002 part of Bayer CropScience, is a biotech company located in Ghent, Belgium. The focus of its activities is the genetic engineering of plants. The company is best known for its work in the development of inse ...

(a joint venture with Schering in crop protection agents and pest control products), HR Vet (veterinary products), Dade Behring (diagnostics), Centeon, Celanese (chemicals), and Messer (chemicals). Merieux has been in the business of selling blood products, and in the 1980s during the

AIDS epidemic The global epidemic of HIV/AIDS (human immunodeficiency virus infection and acquired immunodeficiency syndrome) began in 1981, and is an ongoing worldwide public health issue. According to the World Health Organization (WHO), as of 2021, HIV/AI ...

, Merieux and other companies were involved in scandals related to HIV- contaminated haemophilia blood products that were sold to developing nations. In 2000, Aventis and Millennium Pharmaceuticals, a US biotechnology company formed to discover new drugs based on the then-new science of

genomics Genomics is an interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dim ...

, announced that Aventis would make a $250M investment in Millennium and would pay $200M to Millennium in research fees over five years, one of the largest such deals between a big pharmaceutical company and a biotech company at the time. In late 2000, in the midst of the recall of Starlink, its

genetically modified maize Genetically modified maize (corn) is a genetically modified crop. Specific maize strains have been genetically engineered to express agriculturally-desirable traits, including resistance to pests and to herbicides. Maize strains with both trai ...

product, Aventis announced that it had determined to sell off Aventis Cropscience, the seed and pesticide business unit it had created from the agriculture businesses of its predecessors. In October 2001,

Bayer Bayer AG (, commonly pronounced ; ) is a German multinational corporation, multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of busi ...

and Aventis announced that Bayer would acquire the unit for about $6.6 billion, with the unit becoming Bayer CropScience and making Bayer the world's second-largest agrochemical company behind

Syngenta Syngenta AG is a provider of agricultural science and technology, in particular seeds and pesticides with its management headquarters in Basel, Switzerland. It is owned by ChemChina, a Chinese state-owned enterprise. Syngenta was founded in 2 ...

. In 2003, Aventis entered into a collaboration with Regeneron Pharmaceuticals, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, in the field of cancer, which was then in

Phase I Phase 1, Phase I or Phase One may refer to: Media * Marvel Cinematic Universe: Phase One, six American superhero films from 2008–2012 * ''Phase One'' (Art Ensemble of Chicago album), 1971 * ''Phase One'' (Saga album), 1998 * ''Phase One'', r ...

clinical trials. Aventis invested $45 million in Regeneron and made an upfront payment of $80 million in cash. Regeneron partnered the drug with

Bayer Healthcare Bayer AG (, commonly pronounced ; ) is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceutica ...

in the field of proliferative eye diseases, and under the name Eylea it was approved by the U.S. Food and Drug Administration (FDA) in 2011; after several setbacks in clinical trials, Regeneron and Sanofi got the drug approved in metastatic colorectal cancer in combination with other agents, under the brand name Zaltrap in 2012.

Sanofi-Aventis merger

Sanofi-Aventis was formed in 2004, when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value, and the board of Aventis went so far as to enact poison pill provisions and to invite Novartis to enter merger negotiations. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. The

French French (french: français(e), link=no) may refer to: * Something of, from, or related to France ** French language, which originated in France, and its various dialects and accents ** French people, a nation and ethnic group identified with Franc ...

government played a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis and for Aventis to accept the offer and by rejecting Aventis' poison pill proposal. One of the largest risks in the deal for both sides, was the fate of the patents protecting

Clopidogrel Clopidogrel — sold under the brand name Plavix, among others — is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following t ...

(Plavix) which was one of the top-selling drugs in the world at the time and the major source of Sanofi's revenue.

Post-merger activities

In 2006, Iraqis infected with HIV sued Sanofi and Baxter due to HIV- contaminated haemophilia blood products sold by Merieux in the 1980s. In 2006, the US patents on

clopidogrel Clopidogrel — sold under the brand name Plavix, among others — is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following t ...

(Plavix) were challenged when a Canadian generics company, Apotex, filed an

Abbreviated New Drug Application An Abbreviated New Drug Application (ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. The ANDA is submitted to Food and Drug Administration, FDA's Center for Drug Evaluation and Resea ...

under the

Hatch-Waxman Act The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that encourages the manufacture of generic drugs by the pharmaceutical industry and es ...

, received FDA approval, and started marketing a generic clopidogrel. While Sanofi-Aventis and its partner on the drug,

Bristol Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

(BMS), were able to get an injunction to stop Apotex from selling the drug, the case became complicated when settlement negotiations fell apart twice – the second time due to an

oral agreement An oral contract is a contract, the terms of which have been agreed by spoken communication. This is in contrast to a written contract, where the contract is a written document. There may be written, or other physical evidence, of an oral contract ...

made by BMS CEO Peter Dolan that BMS failed to disclose to the

Federal Trade Commission The Federal Trade Commission (FTC) is an independent agency of the United States government whose principal mission is the enforcement of civil (non-criminal) antitrust law and the promotion of consumer protection. The FTC shares jurisdiction ov ...

during the review of the settlement agreement to ensure that it did not violate

antitrust Competition law is the field of law that promotes or seeks to maintain market competition by regulating anti-competitive conduct by companies. Competition law is implemented through public and private enforcement. It is also known as antitrust l ...

law. When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan being fired by BMS. Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent, which it paid in full by February 2012. Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement, and Apotex lost a jury trial in March 2013. In 2007, Sanofi-Aventis expanded on Aventis' prior relationship with Regeneron Pharmaceuticals; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million each year for five years, under which Regeneron would use its monoclonal antibody

discovery Discovery may refer to: * Discovery (observation), observing or finding something unknown * Discovery (fiction), a character's learning something unknown * Discovery (law), a process in courts of law relating to evidence Discovery, The Discovery ...

platform to create new

biopharmaceuticals A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...

, which Sanofi-Aventis gained the exclusive right to co-develop. In 2009, the companies expanded the deal to $160 million per year and extended it through 2017.Genetic Engineering and Biotechnology News. 11 November 200
Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
/ref> , the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6

receptor Receptor may refer to: * Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse *Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a ...

as a treatment for rheumatoid arthritis, another targeted

nerve growth factor Nerve growth factor (NGF) is a neurotrophic factor and neuropeptide primarily involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It is perhaps the prototypical growth factor, in that it was on ...

for the treatment of pain, and another targeted delta-like ligand 4 as a treatment of cancer. Between 2008, when Chris Viehbacher was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming patent cliffs and the growth of the consumer healthcare segment. In September,

Zentiva Zentiva is a pharmaceutical company based in Prague, Czech Republic. The company is developing, manufacturing and marketing a wide range of generic and OTC products. Zentiva employs more than 4 700 people across Europe and has three manufacturin ...

was acquired for €1.8 billion, expanding the group's eastern European markets presence. In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company in that country, was acquired for about $635 million.Leigh Kamping-Carder for Law360. 20 May 201
Brazil Clears Sanofi's $635M Medley Pharma Buy
/ref> Sanofi outbid

Teva Pharmaceuticals Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include ...

. The deal was approved by Brazil's antitrust authorities in May 2010. Later that year, Indian vaccine manufacturer Shantha Biotechnics was acquired for $784 million. In October Sanofi-Aventis announced that it would lay off about 1,700 US employees (about 25% of its US workforce) due to restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation and oncology. In 2010, U.S. consumer healthcare company Chattem, Inc. was acquired for around $1.9 billion. In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.

Name change, acquisitions and investments

The company dropped the -Aventis suffix of its name on 6 May 2011, after receiving approval at its annual general meeting. The reason given by the company for the change was to make its name easier to pronounce in countries such as China. In 2011,

Genzyme Corporation Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) has been a fully owned subsidiary of Sanofi. In 2010, Genzyme ...

was acquired for around $20.1 billion. This biotechnology company headquartered in Cambridge, Massachusetts specializes in the treatment of

orphan diseases A rare disease is any disease that affects a small percentage of the population. In some parts of the world, an orphan disease is a rare disease whose rarity means there is a lack of a market large enough to gain support and resources for discove ...

, renal diseases, endocrinology, oncology and biosurgery. In January 2012, Sanofi co-invested in the $125 million

Series A financing A series A round (also known as series A financing or series A investment) is the name typically given to a company's first significant round of venture capital financing. The name refers to the class of preferred stock sold to investors in exchan ...

of Warp Drive Bio. Sanofi sought support for its internal cancer research program and also took on an obligation to acquire Warp Drive if certain milestones were met. In January 2014, Genzyme and Alnylam Pharmaceuticals, a US biotechnology company developing RNAi therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under the deal, Genzyme obtained further rights to patisiran, an RNAi treatment for transthyretin-mediated

amyloidosis Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several non-specific and vague signs and symptoms associated with amyloidosis. These include fatigue, peripheral edema, weight ...

– a condition that can result in

familial amyloidotic polyneuropathy Familial amyloid polyneuropathy, also called transthyretin-related hereditary amyloidosis, transthyretin amyloidosis abbreviated also as ATTR (hereditary form), or Corino de Andrade's disease, is an autosomal dominant neurodegenerative disease. It ...

and familial amyloidotic cardiomyopathy - and obtained rights to other compounds in Alnylam's pipeline. In March 2014, Sanofi joined the bidding for Merck & Co.'s over-the-counter health-products unit, the maker of

Coppertone Coppertone is the brand name for an American sunscreen. Coppertone is headquartered in Whippany, New Jersey. Coppertone uses a variety of branding, including the Coppertone girl logo and a distinctive fragrance. Product line The original produ ...

sunblock and

Claritin Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies. This includes allergic rhinitis (hay fever) and hives. It is also available in combination with pseudoephedrine, a decongestant, known as lo ...

allergy medicine; bids were expected to range between $10 billion and $12 billion. In October 2014, Sanofi's directors fired US-resident chief executive Chris Viehbacher, blaming his alleged lack of communication with the board and poor execution of his strategy. Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when

board chairperson

Olivier Brandicourt Olivier Brandicourt (born 13 February 1956) is a French business executive and physician, and the former chief executive officer of Sanofi. Career Olivier Brandicourt studied medicine in Paris and specialized in infectious diseases and tropical ...

(appointed by Sanofi on 19 February 2015) took over. Before Brandicourt even started his new job, French government ministers

Stéphane Le Foll Stéphane Le Foll (; born 3 February 1960) is a French politician serving as Mayor of Le Mans since 2018. A member of the Socialist Party, he was Minister of Agriculture under President François Hollande from 2012 to 2017. Biography Early p ...

and Ségolène Royal attacked the $4.5 million

golden handshake A golden handshake is a clause in an executive employment contract that provides the executive with a significant severance package in the case that the executive loses their job through firing, restructuring, or even scheduled retirement. This can ...

he was getting from Sanofi – and his pay of about $4.7 million a year. Further, in 2014, the business took a 66% stake in Globalpharma, Dubai-based generics manufacturer. In July 2015, Genzyme announced it would acquire the rare cancer drug Caprelsa ( vandetanib) from AstraZeneca for up to $300 million. In the same month in July 2015, the company announced a new global collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof of concept data and $650 million from the development of

REGN2810 Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD- ...

. In June 2016, the company announced it had struck an asset-swap deal with

Boehringer Ingelheim C.H. Boehringer Sohn AG & Co. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical ...

. Sanofi would sell its

animal health division (valuing it at €11.4 billion), whilst acquiring Boehringer's consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash. The deal means Sanofi is now one of the global consumer healthcare leaders by market share. In July 2017, the company announced its intention to acquire Protein Sciences, a privately held, Connecticut-based vaccines biotechnology company, for $650 million and with up to $100 million in milestone achievements. In January 2018, Sanofi announced that it would acquire

Bioverativ Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfi ...

for $11.6 billion and days later announced it would acquire Ablynx for €3.9 billion ($4.8 billion). In December 2019, the company announced it would acquire Synthorx for $2.5 billion ($68 per share), adding the lead product candidate THOR-707 (SAR444245), a form of interleukin-2 (IL-2) being developed for use against multiple solid tumours. In October 2022, Sanofi announced that it had stopped the ongoing Phase 2 tests of THOR-707 (SAR444245) because the drug’s efficacy “was lower than projected”. Sanofi would take a roughly $1.6 billion impairment charge because of delays to the program. In May 2020

Regeneron Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to i ...

announced it would repurchase around $5 billion of its shares, held directly by Sanofi. Prior to the transaction Sanofi held 23.2 million Regeneron shares. In June, the company announced it had agreed a potential $2 billion deal with Translate Bio, expanding an already existing collaboration for COVID-19 treatments. The company agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020. It uses recombinant protein-based technology for Sanofi's flu vaccine along with GSK's pandemic technology and was seeking regulatory approval by the first half of 2021. Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses. In August, Sanofi announced it would acquire

Principia Biopharma Principia may refer to: * '' Philosophiæ Naturalis Principia Mathematica'', Isaac Newton's three-volume work about his laws of motion and universal gravitation * Principia ( "primary buildings"), the headquarters at the center of Roman forts ( l ...

for $3.7 billion, acquiring its

BTK inhibitor Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the ''BTK'' gene in humans. BTK plays a crucial role in B cell development. Structure BTK contains five diffe ...

programme. The acquisition was completed in September 2020. In November, Sanofi announced it would acquire Kiadis Pharma for €308 million (around $359 million, or €5.45 per share) expanding its immuno-oncology pipeline with the acquisition of Kiadis' three clinical compounds: K-NK002 in Phase II trials for

hematopoietic stem cell Hematopoietic stem cells (HSCs) are the stem cells that give rise to other blood cells. This process is called haematopoiesis. In vertebrates, the very first definitive HSCs arise from the ventral endothelial wall of the embryonic aorta within t ...

transplants in blood cancer, K-NK003 for relapsed or refractory acute myeloid leukemia and K-NK-ID101 for COVID-19. In January 2021, Sanofi announced it would buy the British biotech, Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.45 billion. In April, the business announced it would acquire Tidal Therapeutics for up to $470m. in August the company announced it would acquire

Translate Bio Translation is the communication of the Meaning (linguistic), meaning of a #Source and target languages, source-language text by means of an Dynamic and formal equivalence, equivalent #Source and target languages, target-language text. The ...

and its mRNA vaccine technology for $3.2 billion. On 8 September, Sanofi announced it will acquire US biotech company

Kadmon Corporation Kadmon Corporation (originally ''Kadmon Pharmaceuticals'') is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal, founder and former ...

for $1.9 billion On 18 November, it was reported that Sanofi would be investing $180 million in French startup

Owkin Owkin is a medical A.I. company created in 2016 that develops a federated learning A.I. platform to help pharmaceutical companies discover new drugs. Owkin has collaborated with Amgen to demonstrate the ability of A.I. to improve cardiovascular pr ...

, whose predictive algorithms aim to improve the research and development of new cures against cancer. In December, the company announced it would acquire Origimm Biotechnology GmbH and its acne vaccine candidate ( ORI-001), as well as Amunix Pharmaceuticals for an initial $1 billion, plus potentially $200 million in additional milestones. In April 2022, Sanofi broke ground on its biggest industrial investment, a $638m vaccine and enzymes production facility in Tuas, Singapore, targeted for completion in 2025.

Company financials

Note. In 2001—2004 – Sanofi-Synthélabo, in 2004—2011 – Sanofi-Aventis.

Acquisition history

*Sanofi **Sanofi–Aventis *** Aventis (Merged 2004) **** Rhône-Poulenc (Merged 1999) *****Rorer *****Centeon *****Pasteur Merieux *****Rhône-Poulenc Agro *****Rhône-Poulenc Animal Nutrition *****Merial (Sold to

2016) ***** Rhodia ****

(Merged 1999) *****

*****HR Vet ***** Dade Behring *****Centeon ***** Celanese *****Messer *** Sanofi-Synthélabo (Merged 2004) ****Sanofi (Est 1973 as subsidiary of Elf Aquitaine) *****Midy *****

(Acq 1994) ****

Synthélabo Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Syn ...

*****Laboratoires Dausse (Founded 1834, merged 1970) *****Robert & Carrière (Founded 1899, merged 1970) ***

(Acq 2008) ****Leciva Slovakofarma (Acq 2003) ****Sicomed SA Bucharest (Acq 2005) ***Medley Farma (Acq 2009) ***Shantha Biotechnics (Acq 2009) ***Chattem (Acq 2010) ***Nepentes Pharma (Acq 2010) ***BMP Sunstone Corporation (Acq 2010) **

(Acq 2011) ***Whatman Biochemicals Ltd (Acq 1981) ***Koch-Light Laboratories (Acq 1982) ***Integrated Genetics (Acq 1989, spun off 1991) ***Genecore International (Diagnostic enzyme div, acq 1991) ***Medix Biotech, Inc. (Acq 1992) ***Enzymatix Ltd (Acq 1992) ***Vivigen (Acq 1992) ***Virotech (Acq 1993) ***Omni Res srl (Acq 1993) ***Sygena Ltd (Acq 1994) ***BioSurface Technology Inc. (Acq 1994) ***TSI Inc. (Acq 1994) ***PharmaGenics, Inc. (Acq 1997) ***Biomatrix (Acq 2000) ***SangStat Medical Corp. (Acq 2003) ***Ilex Oncology Inc. (Acq 2004) ***Bone Care International Inc. (Acq 2005) ***AnorMED Inc. (Acq 2006) ***Bioenvision (Acq 2007) **Protein Sciences (Acq 2017) **

(Acq 2018) ***True North Therapeutics (Acq 2017) ** Ablynx (Acq 2018) **Synthorx (Acq 2019) **Principia Biopharma (Acq 2020) **Kiadis Pharma (Acq 2020) **Kymab Ltd (Acq 2021) **Tidal Therapeutics (Acq 2021) **Translate Bio (Acq 2021) **

(Acq 2021) **Origimm Biotechnology GmbH (Acq 2021) **Amunix Pharmaceuticals (Acq 2021)

Products

The following products are found on the Sanofi Genzyme website.

Generic drug A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active ch ...

names are given in parentheses following the brand name. – Autoimmune *

Aubagio Teriflunomide, sold under the brand name Aubagio, is the active metabolite of leflunomide. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-y ...

( Teriflunomide), small molecule for

multiple sclerosis Multiple (cerebral) sclerosis (MS), also known as encephalomyelitis disseminata or disseminated sclerosis, is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This d ...

. Approved by the FDA in September 2012. *

Auvi-Q An epinephrine autoinjector (or adrenaline autoinjector, also known by the trademark EpiPen) is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the ...

( Epinephrine autoinjector), licensed from Intelliject and approved by the FDA in 2012, for emergency treatment of life-threatening allergic reactions. Product recall and effects: The Epinephrine auto-injection devices made by Sanofi SA currently on the market in the U.S. and Canada were voluntarily recalled on 28 October 2015. The reason stated by Sanofi was that the products have been found to potentially have inaccurate dosage delivery, which may include failure to deliver drug. Sanofi US also added the following warning: If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life‑threatening condition. In its news release on 28 October 2015, Sanofi Canada stated that it was "actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible. Canadian customers were asked to immediately return the Allerject product to their local pharmacy to obtain an alternate epinephrine auto-injector." The U.S. Food and Drug Administration (FDA) also filed a news release confirming that the recall involves all Auvi-Q currently on the market in the U.S. The FDA release went on to provide information for consumers re: exchanging the device for another brand of product, also provided on the Auvi-Q web site. Sanofi US will provide reimbursement for out of pocket costs incurred for the purchase of new, alternate epinephrine auto-injectors with proof of purchase. The alternate products expected to most commonly replace the recalled Sanofi devices are the EpiPens made by Mylan in the US and by Pfizer—under license from Mylan—in Canada. Mylan already had an 85% market share of the auto-injectors in the US in the first half of 2015. Maylan was expected to benefit from the recall by its competitor Sanofi, according to a report published in the Fierce Pharma newsletter of 2 November 2015: "....it is very hard to see Auvi-Q returning to the market, as it will need to be redesigned and face uphill battle to recapture patient trust after the recall," Bernstein analyst Ronny Gal wrote in a note to clients. Gal also believes that the company will eventually have 95% of the Epinephrine auto-injector market, according to another Fierce Pharma report on 3 November 2015. – Cardiovascular *

Adenoscan Adenosine (symbol A) is an organic compound that occurs widely in nature in the form of diverse derivatives. The molecule consists of an adenine attached to a ribose via a β-N9- glycosidic bond. Adenosine is one of the four nucleoside building ...

(

Adenosine Adenosine ( symbol A) is an organic compound that occurs widely in nature in the form of diverse derivatives. The molecule consists of an adenine attached to a ribose via a β-N9-glycosidic bond. Adenosine is one of the four nucleoside building ...

), for arrhythmias, marketed by Astellas. *

Altace Ramipril, sold under the brand name Altace among others, is an ACE inhibitor type medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It can also be used as a preventative medication in patients over 55 year ...

( Ramipril), for

hypertension Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. High blood pressure usually does not cause symptoms. Long-term high bl ...

, marketed by Pfizer. * Arixtra ( Fondaparinux), for thrombosis, marketed by GlaxoSmithKline and now owned by Mylan. *

Avalide Irbesartan, sold under the brand name Avapro among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. Versio ...

( Irbesartan), for

, marketed by Bristol-Myers Squibb. * Avapro ( Irbesartan), for

, marketed by Bristol-Myers Squibb. *

Cardizem Diltiazem, sold under the brand name Cardizem among others, is a calcium channel blocker medication used to treat high blood pressure, angina, and certain heart arrhythmias. It may also be used in hyperthyroidism if beta blockers cannot be us ...

(

Diltiazem Diltiazem, sold under the brand name Cardizem among others, is a calcium channel blocker medication used to treat high blood pressure, angina, and certain heart arrhythmias. It may also be used in hyperthyroidism if beta blockers cannot be used ...

), for

, Now owned by Bausch Health. *

Cholestagel Colesevelam is a bile acid sequestrant administered orally. It was developed by GelTex Pharmaceuticals and later acquired by Genzyme. It is marketed in the U.S. by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestage ...

( Colesevelam), for low-calorie diet and exercise. *

Cordarone Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias. This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillat ...

( Amiodarone), for heart rhythm problems. * Iprivask (

Desirudin Hirudin is a naturally occurring peptide in the salivary glands of blood-sucking leeches (such as ''Hirudo medicinalis'') that has a blood anticoagulant property. This is fundamental for the leeches’ habit of feeding on blood, since it keeps a h ...

), for atherothrombosis, Now owned by Bausch Health. *

Kynamro Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the cont ...

(

Mipomersen Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the cont ...

), an antisense drug invented by

Isis Pharmaceuticals Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (In ...

and acquired by Genzyme in 2008, (pre-Sanofi) and approved by the FDA in 2013, for the orphan disease homozygous familial hypercholesterolemia. *

Lasix Furosemide is a loop diuretic medication used to treat edema, fluid build-up due to heart failure, hepatic cirrhosis, liver scarring, or kidney disease. It may also be used for the treatment of hypertension, high blood pressure. It can be take ...

( Furosemide), for edema. *

Lovenox Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following c ...

(

Enoxaparin Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following c ...

), for thrombosis, (its biggest seller in 2008). * Multaq ( Dronedarone), for cardiac arrhythmias. *

Nitrolingual Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication used for heart failure, high blood pressure, anal fissures, painful periods, and to treat and prevent chest pain caused by decreased blood flow to the heart (angina) or ...

(

Nitroglycerin Nitroglycerin (NG), (alternative spelling of nitroglycerine) also known as trinitroglycerin (TNG), nitro, glyceryl trinitrate (GTN), or 1,2,3-trinitroxypropane, is a dense, colorless, oily, explosive liquid most commonly produced by nitrating g ...

), for chest pain and angina, marketed by G. Pohl-Boskamp GmbH & Co. * Plavix (

), for atherothrombosis, marketed by Bristol-Myers Squibb. *

Praluent Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs t ...

(

Alirocumab Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for hypercholesterolemia, high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal anti ...

), for heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease, marketed by Regeneron. *

Ranexa Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Benefits appear smaller in women than men. It ...

(

Ranolazine Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Benefits appear smaller in women than men. It ...

), for stable angina, marketed by Gilead Sciences. – Dermatology *

Dupixent Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. It is ...

(

Dupilumab Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. It is ...

), for eczema, marketed by Regeneron. *

Dynabac Dirithromycin is a macrolide glycopeptide antibiotic. Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared by condensation of the latter with 2-(2-methoxyethoxy)acetaldehyde. The 9N, 11O-oxazine rin ...

(

Dirithromycin Dirithromycin is a macrolide glycopeptide antibiotic. Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared by condensation of the latter with 2-(2-methoxyethoxy)acetaldehyde. The 9N, 11O-oxazine rin ...

), for acute bacteria exacerbations. * Sklice ( Ivermectin), for head lice, now owned by Arbor Pharmaceuticals. – Diabetes * Adlyxin ( Lixisenatide), for type 2 diabetes mellitus. * Admelog (insulin lispro), for type 1 and type 2 diabetes mellitus. *

Afrezza Inhalable insulin is a powdered form of insulin, delivered with an inhaler into the lungs where it is absorbed. In general inhaled insulins have been more rapidly absorbed than Subcutaneous injection, subcutaneous injected insulin, with faster peak ...

(

Inhalable insulin Inhalable insulin is a powdered form of insulin, delivered with an inhaler into the lungs where it is absorbed. In general inhaled insulins have been more rapidly absorbed than Subcutaneous injection, subcutaneous injected insulin, with faster peak ...

), for type 1 and type 2 diabetes mellitus. * Amaryl (

Glimepiride Glimepiride, is an anti-diabetic medication used to treat type 2 diabetes. It is less preferred than metformin. Use is recommended together with diet and exercise. It is taken by mouth. Glimepiride takes up to three hours for maximum effect and l ...

), for type 2 diabetes mellitus. *

Apidra Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was d ...

(insulin glulisine), for type 1 and type 2 diabetes mellitus. *

Diabeta Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended f ...

(

Glyburide Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended f ...

), for type 2 diabetes mellitus. *

Glucophage Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. I ...

( Metformin), for type 2 diabetes mellitus, marketed by EMD Serono. * Insuman ( Human insulin), for type 1 and type 2 diabetes mellitus. *

Lantus Insulin glargine, sold under the brand name Lantus among others, is a long-acting modified form of medical insulin, used in the management of type I and type II diabetes. It is typically the recommended long acting insulin in the United King ...

(insulin glargine), for type 1 and type 2 diabetes mellitus. * Soliqua (insulin glargine/lixisenatide), for type 2 diabetes mellitus. * Toujeo (insulin glargine), for type 1 and type 2 diabetes mellitus. – Endocrinology * Adlyxin ( Lixisenatide), for type 2 diabetes mellitus. * Admelog (insulin lispro), for type 1 and type 2 diabetes mellitus. *

(

), for type 1 and type 2 diabetes mellitus. * Amaryl (

), for type 2 diabetes mellitus. *

(insulin glulisine), for type 1 and type 2 diabetes mellitus. *

( Colesevelam), for low-calorie diet and exercise. *

(

), for type 2 diabetes mellitus. *

( Metformin), for type 2 diabetes mellitus, marketed by EMD Serono. *

Hectorol Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease. It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion ...

(

Doxercalciferol Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease. It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion. ...

), for parathyroid hormone. * Insuman ( Human insulin), for type 1 and type 2 diabetes mellitus. *

(insulin glargine), for type 1 and type 2 diabetes mellitus. *

Skelid Tiludronic acid (INN; also known as tiludronate) is a bisphosphonate used for treatment of Paget's disease of bone (osteitis deformans) in human medicine. It has the tradename Skelid. In veterinary medicine, tiludronic acid is used to treat navi ...

( Tiludronic acid), for Paget's disease of bone. * Soliqua (insulin glargine/lixisenatide), for type 2 diabetes mellitus. * Toujeo (insulin glargine), for type 1 and type 2 diabetes mellitus. – Gastroenterology *

Lanzor Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. Effectiveness is similar to ...

(

Lansoprazole Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. Effectiveness is similar to ...

), for acid reflux disease. * Seprafilm ( Adhesion barrier), for internal adhesions. *

Zaltrap Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the Europ ...

( Aflibercept), recombinant

fusion protein Fusion proteins or chimeric (kī-ˈmir-ik) proteins (literally, made of parts from different sources) are proteins created through the joining of two or more genes that originally coded for separate proteins. Translation of this ''fusion gene'' r ...

, approved in metastatic colorectal cancer in combination with other agents in 2012, marketed by Regeneron. –

Hematology Hematology ( always spelled haematology in British English) is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. It involves treating diseases that affect the produc ...

Alprolix Factor IX (or Christmas factor) () is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B. It was discovered in 1952 after a young boy named Stephen Christmas ...

( Factor IX), for hemophilia B. * Arixtra ( Fondaparinux), for thrombosis, marketed by GlaxoSmithKline and now owned by Mylan. *

Cablivi Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. This drug was developed by Ablynx NV. On 30 August 2018, it was approved ...

(

Caplacizumab Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. This drug was developed by Ablynx NV. On 30 August 2018, it was approved i ...

), for thrombosis. *

Campath Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS ...

( Alemtuzumab), for

. *

Clolar Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute ...

(

Clofarabine Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute ...

), for leukemia. * Eloctate ( Factor VIII), for hemophilia A. *

Ferrlecit Sodium ferric gluconate complex, sold under the brand name Ferrlecit, is an intravenously administered iron medication for the treatment of iron deficiency anemia in adults and in children aged six years and older with chronic kidney disease rece ...

(

Sodium ferric gluconate complex Sodium ferric gluconate complex, sold under the brand name Ferrlecit, is an intravenously administered iron medication for the treatment of iron deficiency anemia Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as ...

), for iron deficiency anemia. *

Fludara Fludarabine is a purine analogue and antineoplastic agent. It is generally used as its 5-O-phosphorylated form known as fludarabine phosphate, sold under the brand name Fludara among others. It is a chemotherapy medication used in the treatmen ...

(

Fludarabine Fludarabine is a purine analogue and antineoplastic agent. It is generally used as its 5-O-phosphorylated form known as fludarabine phosphate, sold under the brand name Fludara among others. It is a chemotherapy medication used in the treatmen ...

), for leukemia. *

Mozobil Plerixafor (INN and USAN, trade name Mozobil) is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug ...

( Plerixafor), for macrocycle, approved by the

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...

for peripheral blood stem cell mobilizer for non-Hodgkin's lymphoma and multiple myeloma in December 2008. * Oforta (

), for leukemia. * Thymoglobulin, for hemophilia A. * Zemaira (Alpha-1 antitrypsin), for chronic augmentation, Now owned by CSL Behring. – Infectious diseases * Antibiotics: * Amoklavin (Amoxicillin/clavulanic acid) * Claforan (Cefotaxime) * Priftin (Rifapentine) * Suprax (Cefixime) * Tavanic (Levofloxacin) * Vaccines: **Bacterial diseases: * ActHIB (Hib vaccine) * Adacel (vaccine), Adacel (DPT vaccine) * Daptacel (DPT vaccine) * Dengvaxia (Dengue vaccine) * Menactra (Meningococcal vaccine, Meningococcal infections) * Mycobax (Tuberculosis vaccine) * Pentacel (DTaP-IPV/Hib vaccine) * Pneumo 23 (Pneumococcal vaccine, Pneumococcal infections) * Quadracel (DTaP-IPV/Hib vaccine) * Shanchol (Cholera vaccine) * Synercid (Quinupristin/dalfopristin), marketed by Pfizer. * Tenivac (Tetanus vaccine) * Tripedia (DPT vaccine), discontinued in 2012. * Tubersol (Tuberculosis vaccine) * Typhim Vi (Typhoid fever) * Vaccin Tetanique Pasteur (Tetanus vaccine) **Viral diseases: * ACAM 2000 (Smallpox vaccine), eradicated in 1980 (vaccine produced as a measure in response to the threat of bioterrorism). * Avaxim (Hepatitis A vaccine) * Flublok (Influenza vaccine) * Fluzone (Influenza vaccine) * Hbvaxpro (Hepatitis B vaccine) * Imovax Polio (Polio vaccine) * Imovax Rabies (Rabies vaccine) * Ipol (Polio vaccine) * Ixiaro (Japanese encephalitis) * M-M-RVaxPro (MMR vaccine) * Rouvax (Measles vaccine) * Rudivax (Rubella vaccine) * Stamaril (Yellow fever vaccine) * Vaxigrip (Influenza vaccine) * YF-VAX (Yellow fever vaccine) – Metabolic * Actonel (Risedronic acid), for osteoporosis and Paget's disease of bone, Paget's disease, now owned by Allergan. * Renagel (Sevelamer) hydrochloride, for Chronic kidney disease, end stage renal disease. * Renvela (Sevelamer) hydrochloride, for Chronic kidney disease, end stage renal disease. – Neurology * Ambien (Zolpidem), for insomnia. * Ambien CR (Zolpidem), for insomnia. *

( Teriflunomide), for

. * Depakine (Valproic acid), for epilepsy, now owned by AbbVie. * Depakote (Valproate semisodium), for epilepsy, now owned by AbbVie. * Hyalgan (Sodium hyaluronate), for blood tests. * Lemtrada ( Alemtuzumab), for

. * Pediapred (Prednisolone), for

. * Rilutek (Riluzole), for ALS. * Sabril (Vigabatrin), for epilepsy, marketed by Lundbeck. – Oncology * Anzemet (Dolasetron), for nausea and vomiting. *

( Alemtuzumab), for

. * Caprelsa (Vandetanib), for breast, colorectal cancer and female infertility. *

(

), for leukemia. * Clomid (Clomifene), for female infertility. *

(

), for eczema, marketed by Regeneron. * Eligard (Leuprorelin), for prostate cancer, marketed by Astellas. * Elitek (Rasburicase), for the treatment to help stop uric acid. * Eloxatin (Oxaliplatin), for colorectal cancer. *

(

), for leukemia. * Gliadel Wafer (Carmustine), for cancer, now owned by Arbor Pharmaceuticals. * Jevtana (Cabazitaxel), for prostate cancer. * Kevzara (Sarilumab), for blood tests, lung cancer, lung and prostate cancer, marketed by Regeneron. * Libtayo (Cemiplimab), for squamous cell skin cancer, marketed by Regeneron. *

( Plerixafor), macrocycle, approved by the

for peripheral blood stem cell mobilizer for non-Hodgkin's lymphoma and multiple myeloma in December 2008. * Oforta (

), for leukemia. * Taxotere (Docetaxel), for breast cancer, breast, lung cancer, lung and prostate cancer. * Uroxatral (Alfuzosin), for benign prostatic hyperplasia. *

( Aflibercept), recombinant

, approved in metastatic colorectal cancer in combination with other agents in 2012, marketed by Regeneron. – Other * Aldurazyme (Laronidase), for hurler syndrome. * Aplenzin (Bupropion), for depression and quit smoking. * Captique (Dermal filler), for facial wrinkles. * Carticel (Knee cartilage replacement therapy), for knee pain. * Cerdelga (Eliglustat), for type 1 gaucher disease. * Ceredase (Alglucerase), for Gaucher's disease. * Cerezyme (Imiglucerase), for Gaucher's disease. * Elaprase (Idursulfase), marketed by Shire. * Epicel (cultured epidermal autografts), for thickness burns. * Fabrazyme (Agalsidase), for Fabry disease. * Flagyl (Metronidazole), for vaginal infections, marketed by Pfizer. * Hylaform Plus (Injectable filler), for facial wrinkles. * Lumizyme (Alglucosidase alfa), for Pompe disease. * Myozyme (Alglucosidase alfa), for Pompe disease. * Sculptra (Polylactic acid), for facial fat loss. * Thyrogen (Thyroid-stimulating hormone), for thyroid cancer. – Over the counter * Allegra (Fexofenadine), for allergic rhinitis. * Buscopan (Hyoscine butylbromide), for abdominal pain. * Maalox (Calcium carbonate#Health and dietary applications, Calcium carbonate), an antacid. * Nasacort (Triamcinolone), for allergic rhinitis. * Novaldol (Paracetamol), for pain and fever. * Unisom (Doxylamine), for night-time allergy and cold relief. * Xyzal (Levocetirizine), for allergic rhinitis, marketed by UCB. * Telfast for Seasonal Allergy Relief * Enterogermina Medicine for Diarrhea – Pain * Bi-profined (Ketoprofen), for pain. * Solpadol (Codeine), for chronic pain. – Respiratory and inflammatory diseases * Atrovent (Ipratropium bromide), for asthma, marketed by Boehringer Ingelheim. * Azmacort (Triamcinolone), for asthma. *

(

), for acute bacterial exacerbations. * Ketek (Telithromycin), for community acquired pneumonia. * Priftin (Rifapentine), for tuberculosis. * Rifadin (Rifampin), for tuberculosis. * Rifamate (Isoniazid/rifampicin), for tuberculosis. * Rifater (Rifampicin/isoniazid/pyrazinamide), for tuberculosis. * Tilade (Nedocromil), for asthma. * Zagam (Sparfloxacin), for chronic bronchitis. * Zemaira (Alpha-1 antitrypsin), for chronic augmentation, now owned by CSL Behring. * Mucosolvan Medicine for Cough – Rheumatology * Arava (Leflunomide), for rheumatoid arthritis, rheumatoid and psoriatic arthritis. * Kevzara (Sarilumab), for blood tests, lung cancer, lung and prostate cancer, marketed by Regeneron. * Primaquine (Primaquine), for malaria. * Synvisc (Hyaluronic acid), for knee pain. – Urology * Ditropan XL (Oxybutynin chloride), for bladder relief, marketed by Janssen. * Eligard (Leuprorelin), for prostate cancer, marketed by Astellas. * Flomax (Tamsulosin), for bladder relief, marketed by Astellas. The company also produces a broad range of over-the-counter products, among them Fexofenadine, Allegra, IcyHot for muscle pain, Gold Bond medicated powder, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo. These brands were acquired in 2010, when Sanofi-Aventis purchased Chattem.

Pipeline

, Sanofi was in a race with Amgen and Pfizer to win approval for a PCSK9 inhibitor, drug that inhibits PCSK9, a protein that slows the clearance of low-density lipoprotein (LDL) cholesterol – the form of cholesterol that leads to heart attacks. Sanofi's drug was discovered by Regeneron Pharmaceuticals and is called alirocumab. An FDA warning in March 2014, about possible cognitive adverse effects of PCSK9 inhibition threw the competition into disarray, as the FDA asked companies to include neurocognitive testing into their Phase III clinical trials. In 2013, Sanofi announced that another candidate from its collaboration with Regeneron, the monoclonal antibody against the interleukin 6 receptor, sarilumab, had better efficacy than placebo in its first Phase III trial for rheumatoid arthritis.

Management

* Serge Weinberg, chairman of the board, chairman * Paul Hudson (businessman), Paul Hudson, CEO, chief executive officer * Jean-François Dehecq was the general manager of Sanofi from its creation in 1973 until 2007. * Jean-Baptiste Chasseloup de Chatillon, Chief financial officer, CFO

Stockholders

As of 31 December 2013: * Breakdown of share ownership: 8.93% by L'Oréal, 0.27% treasury shares and 1.31% stock option, employees. The remaining 89.49% were publicly traded.

Head office

In January 2012, Sanofi moved its head office location to 54, Rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent. Sanofi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominant style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace, moved to Paris. In November 2022, Sanofi moved into its new global headquarters in the 17th arrondissement of Paris, at 46-48 Avenue de la Grande Armée.

Collaborative research

In addition to internal research and development activities Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of Pre-clinical development, non-clinical safety assessment is the Innovative Medicines Initiative, InnoMed PredTox project The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission. In June 2010, Sanofi and the Charité, Charité University of Berlin signed a cooperation agreement for the research and development of medicines and therapies. On 25 October 2012, Sanofi said its earnings for the third quarter slumped as generic competitors ate into profits of its Eloxatin cancer treatment.

Sanofi Pasteur

In 2005, Sanofi Pasteur, vaccines division of Sanofi Group, was awarded a $97 Million United States Department of Health and Human Services (HHS) contract.

BCG supply shortage 2012-

In 2011, a Sanofi Pasteur plant flooded, causing it problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain, such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012, the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. The Toronto Sanofi plant On 29 October 2014 Health Canada gave the permission for Sanofi to resume production of BCG.

COVID-19 vaccine

Sanofi together with GSK signed a deal with US government's Operation Warp Speed to provide 100 million doses COVID-19 vaccine for up to US$2.1 billion, if the vaccine is approved. As of August 2020, COVID-19 vaccine development in Sanofi underscores its fundamental competitiveness weakness, that management has been struggling and failed to deal with for past many years beyond cutting more cost. Unfortunately, even though Sanofi-GSK approach is based on pre-existing, approved platform and technology (as with Flublok flu) without reinventing the wheel of the necessary infrastructure, the company lagged behind many other rivals in delivering a working vaccine. Sanofi planned to start Phase 1 clinical testing only in September and expected emergency use approval in the first half of 2021. Competitors such as Novavax had already completed Phase 1 with promising results and Moderna-NIH had already initiated its Phase 3 trial. According to CNBC reports, as part of the 2.1 billion US government deal, more than 750 million goes to supporting Sanofi-GSK in vaccine development and clinical trials. Sanofi turns out "accelerate" the development via smaller biotech firm Translate Bio, with a 425 million partnership. At the end of September 2021, Sanofi announced it would stop developing its mRNA COVID-19 vaccine. Despite promising results the drug would not continue to Phase 3 trials, with the company stating that it would be 'too late to reach the market.'

Associations

Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), Biotechnology Industry Organization (BIO), and Pharmaceutical Research and Manufacturers of America (PhRMA). Sanofi's vaccine subsidiary, Sanofi Pasteur, is a member of EuropaBio. In June 2021, Sanofi partners with Capgemini, Orange S.A., Orange & Generali Italia, Generali to launch Future4care, an all-European start-up accelerator centered on digital health.

Aventis Foundation

The Aventis Foundation, a Germany, German charitable trust, was established in 1996, as the Hoechst Foundation with an Financial endowment, endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. The foundation promotes cultural and scientific projects, specifically focused on the Frankfurt Rhine-Main area.

Notes

References

External links

* {{Authority control, state=expanded Sanofi, Biotechnology companies of France CAC 40 Companies in the Euro Stoxx 50 Companies listed on Euronext Paris French brands French companies established in 1973 Healthcare companies of France Health care companies established in 1973 Multinational companies headquartered in France Orphan drug companies Pharmaceutical companies established in 1973 Pharmaceutical companies of France